A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Bipolar disorder (BD) is a major psychiatric disorder that is easily misdiagnosed. Patient adherence to a treatment regimen is of utmost importance for successful outcomes in BD. Several trials of antipsychotics suggested that depot antipsychotics, including long-acting first- and second-generation agents, are effective in preventing non-adherence, partial adherence, and in reducing relapse in BD. Various long-acting injectable (LAI) antipsychotics are available, including fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, paliperidone palmitate, and aripiprazole monohydrate. Due to the increasing number of BD patients receiving LAI antipsychotics, treatment guidelines have been developed. However, the clinical applicability of LAI antipsychotics remains a global cause for concern, particularly in Asian countries. Expert physicians from Taiwan participated in a consensus meeting, which was held to review key areas based on both current literature and clinical practice. The purpose of this meeting was to generate a practical and implementable set of recommendations for LAI antipsychotic use to treat BD; target patient groups, dosage, administration, and adverse effects were considered. Experts recommended using LAI antipsychotics in patients with schizophrenia, rapid cycling BD, BD I, and bipolar-type schizoaffective disorder. LAI antipsychotic use was recommended in BD patients with the following characteristics: multiple episodes and low adherence; seldom yet serious episodes; low adherence potential per a physician’s clinical judgment; preference for injectable agents over oral agents; and multiple oral agent users still experiencing residual symptoms.
Abstract
Bipolar disorder (BD) is a major psychiatric disorder that is easily misdiagnosed. Patient adherence to a treatment regimen is of utmost importance for successful outcomes in BD. Several trials of antipsychotics suggested that depot antipsychotics, including long-acting first- and second-generation agents, are effective in preventing non-adherence, partial adherence, and in reducing relapse in BD. Various long-acting injectable (LAI) antipsychotics are available, including fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, paliperidone palmitate, and aripiprazole monohydrate. Due to the increasing number of BD patients receiving LAI antipsychotics, treatment guidelines have been developed. However, the clinical applicability of LAI antipsychotics remains a global cause for concern, particularly in Asian countries. Expert physicians from Taiwan participated in a consensus meeting, which was held to review key areas based on both current literature and clinical practice. The purpose of this meeting was to generate a practical and implementable set of recommendations for LAI antipsychotic use to treat BD; target patient groups, dosage, administration, and adverse effects were considered. Experts recommended using LAI antipsychotics in patients with schizophrenia, rapid cycling BD, BD I, and bipolar-type schizoaffective disorder. LAI antipsychotic use was recommended in BD patients with the following characteristics: multiple episodes and low adherence; seldom yet serious episodes; low adherence potential per a physician’s clinical judgment; preference for injectable agents over oral agents; and multiple oral agent users still experiencing residual symptoms.
참고문헌 (38)
- El-Hage W., "Emerging treatments in the management of bipolar disorder-focus on risperidone long acting injection", Neuropsychiatr Dis Treat, 6, pp.455~464 (2010)
- Kemp DE., "Longacting risperidone : a review of its role in the treatment of bipolar disorder", Adv Ther, 26, pp.588~599 (2009)
- Simon GE., "Mood symptoms, functional impairment, and disability in people with bipolar disorder : specific effects of mania and depression", J Clin Psychiatry, 68, pp.1237~1245 (2007)
- Osby U., "Excess mortality in bipolar and unipolar disorder in Sweden", Arch Gen Psychiatry, 58, pp.844~850 (2001)
- Yatham LN., "Canadian Network for Mood and Anxiety Treatments(CANMAT)guidelines for the management of patients with bipolar disorder : update 2007", Bipolar Disord, 8, pp.721~739 (2006)
- Sajatovic M., "Treatment adherence with antipsychotic medications in bipolar disorder", Bipolar Disord, 8, pp.232~241 (2006)
- El-Mallakh RS., "Medication adherence and the use of long-acting antipsychotics in bipolar disorder", J Psychiatr Pract, 13, pp.79~85 (2007)
- Rainer MK., "Risperidone long-acting injection : a review of its long term safety and efficacy", Neuropsychiatr Dis Treat, 4, pp.919~927 (2008)
- Gutiérrez-Rojas L., "Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample", J Affect Disord, 127, pp.77~83 (2010)
- Kennedy WK., "When and how to use long-acting injectable antipsychotics", Current Psychiatry, 11, pp.40~43 (2012)
- Taylor D., "Psychopharmacology and adverse effects of antipsychotic long-acting injections : a review. Br J Psychiatry Suppl, 52", S13-S19 (2009)
- Janssen Pharmaceuticals., (2011), :Division of Ortho-McNeil-Janssen Pharmaceuticals Inc
- Gopalakrishna G., "Long-acting injectable aripiprazole : how might it fit in our tool box?", Clin Schizophr Relat Psychoses, 7, pp.87~92 (2013)
- Otsuka Pharmaceutical Company., (2013), Otsuka Pharmaceutical Company
- Gigante AD., "Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder", CNS Drugs, 26, pp.403~420 (2012)
- American Psychiatric Association., "Practice guideline for the treatment of patients with bipolar disorder(revision)", Am J Psychiatry, 159, pp.1~50 (2002)
- Macfadden W., "A randomized, double-blind, placebocontrolled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently", Bipolar Disord, 11, pp.827~839 (2009)
- Vieta E., "A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder", Eur Neuropsychopharmacol, 22, pp.825~835 (2012)
- Yatham LN., "A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder", Acta Psychiatr Scand Suppl, (434), pp.50~56 (2007)
- Savas HA., "Use of long-acting risperidone in the treatment of bipolar patients", J Clin Psychopharmacol, 26, pp.530~531 (2006)
- Han C., "Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1219~1223 (2007)
- Malempati RN., "Depot risperidone in the outpatient management of bipolar disorder : a 2-year study of 10 patients", Int Clin Psychopharmacol, 23, pp.88~94 (2008)
- Quiroz JA., "Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder", Biol Psychiatry, 68, pp.156~162 (2010)
- Macfadden W., "Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms", BMC Psychiatry, 11, pp.171~ (2011)
- Bobo WV., "Risperidone long-acting injectable(Risperdal ConstaⓇ)for maintenance treatment in patients with bipolar disorder", Expert Rev Neurother, 10, pp.1637~1658 (2010)
- Gray R., "Antipsychotic long-acting injections in clinical practice: medication management and patient choice", Br J Psychiatry Suppl, 52, pp.S51~S56 (2009)
- Geddes JR., "Treatment of bipolar disorder", Lancet, 381, pp.1672~1682 (2013)
- El-Mallakh RS., "Current and emerging therapies for the management of bipolar disorders", J Cent Nerv Syst Dis, 3, pp.189~197 (2011)
- Llorca PM., "Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness", BMC Psychiatry, 13, pp.340~ (2013)
- Yatham LN., "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)collaborative update of CANMAT guidelines for the management of patients with bipolar disorder : update 2013", Bipolar Disord, 15, pp.1~44 (2013)
- Goodwin GM; Consensus Group of the British Association for Psychopharmacology., "Evidence-based guidelines for treating bipolar disorder : revised second edition--recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 23, pp.346~388 (2009)
- Grunze H., "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : update 2012 on the long-term treatment of bipolar disorder", World J Biol Psychiatry, 14, pp.154~219 (2013)
- Grunze H., "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : update 2009 on the treatment of acute mania", World J Biol Psychiatry, 10, pp.85~116 (2009)
- Grunze H., "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : update 2010 on the treatment of acute bipolar depression", World J Biol Psychiatry, 11, pp.81~109 (2010)
- National Collaborating Centre for Mental Health(UK)., "Bipolar disorder : the management of bipolar disorder in adults, children and adolescents, in primary and secondary care" (2006), British Psychological Society
- Crismon ML., "Texas medication algorithm project procedural manual : bipolar disorder algorithms" (2007), Texas Department of State Health Services
- Bai YM., "Taiwan consensus of pharmacological treatment for bipolar disorder", J Chin Med Assoc, 76, pp.547~556 (2013)
- Takeuchi H., "Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia : an open-label, randomized, controlled, pilot study", Schizophr Bull, 39, pp.993~998 (2013)